



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUNE 29, 2020

PTAS

JANET TSE
C/O GENENTECH, INC.
1 DNA WAY, M.S. 49
SOUTH SAN FRANCISCO, CA 94080

506127987

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 06/26/2020

REEL/FRAME: 053059/0350
NUMBER OF PAGES: 17

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: P35574-US, -US-1, WO-1

ASSIGNOR:
GRANDNER, JESSICA MARIE

DOC DATE: 06/11/2020

ASSIGNOR:
SHORE, DANIEL G.M.

DOC DATE: 06/10/2020

ASSIGNOR:
BRYAN, MARIAN C.

DOC DATE: 06/10/2020

ASSIGNEE:
GENENTECH, INC.
1 DNA WAY
SOUTH SAN FRANCISCO, CALIFORNIA
94080

APPLICATION NUMBER: 16902499

FILING DATE: 06/16/2020

PATENT NUMBER:

ISSUE DATE:

TITLE: PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF

APPLICATION NUMBER: 63035381 FILING DATE: 06/05/2020
PATENT NUMBER: ISSUE DATE:
TITLE: PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES
THEREOF

APPLICATION NUMBER: FILING DATE: 06/16/2020
PATENT NUMBER: ISSUE DATE:
PCT NUMBER: US2020037853
TITLE: PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES
THEREOF

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>JESSICA MARIE GRANDNER</td><td>06/11/2020</td></tr><tr><td>DANIEL G.M. SHORE</td><td>06/10/2020</td></tr><tr><td>MARIAN C. BRYAN</td><td>06/10/2020</td></tr></tbody></table>	Name	Execution Date	JESSICA MARIE GRANDNER	06/11/2020	DANIEL G.M. SHORE	06/10/2020	MARIAN C. BRYAN	06/10/2020			
Name	Execution Date										
JESSICA MARIE GRANDNER	06/11/2020										
DANIEL G.M. SHORE	06/10/2020										
MARIAN C. BRYAN	06/10/2020										
RECEIVING PARTY DATA											
<table border="1"><tr><td>Name:</td><td>GENENTECH, INC.</td></tr><tr><td>Street Address:</td><td>1 DNA WAY</td></tr><tr><td>City:</td><td>SOUTH SAN FRANCISCO</td></tr><tr><td>State/Country:</td><td>CALIFORNIA</td></tr><tr><td>Postal Code:</td><td>94080</td></tr></table>	Name:	GENENTECH, INC.	Street Address:	1 DNA WAY	City:	SOUTH SAN FRANCISCO	State/Country:	CALIFORNIA	Postal Code:	94080	
Name:	GENENTECH, INC.										
Street Address:	1 DNA WAY										
City:	SOUTH SAN FRANCISCO										
State/Country:	CALIFORNIA										
Postal Code:	94080										
PROPERTY NUMBERS Total: 3											
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>63035381</td></tr><tr><td>Application Number:</td><td>16902499</td></tr><tr><td>PCT Number:</td><td>US2020037853</td></tr></tbody></table>	Property Type	Number	Application Number:	63035381	Application Number:	16902499	PCT Number:	US2020037853			
Property Type	Number										
Application Number:	63035381										
Application Number:	16902499										
PCT Number:	US2020037853										
CORRESPONDENCE DATA											
Fax Number: (650)952-9881											
Phone: 6502252906											
Email: jet@gene.com											
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>											
Correspondent Name: JANET TSE											
Address Line 1: C/O GENENTECH, INC.											
Address Line 2: 1 DNA WAY, M.S. 49											
Address Line 4: SOUTH SAN FRANCISCO, CALIFORNIA 94080											
ATTORNEY DOCKET NUMBER:	P35574-US, -US-1, WO-1										
NAME OF SUBMITTER:	JANET TSE										

Signature:	/Janet Tse/
Date:	06/26/2020
Total Attachments: 15 source=P35574 Add inv-GNE to record#page1.tif source=P35574 Add inv-GNE to record#page2.tif source=P35574 Add inv-GNE to record#page3.tif source=P35574 Add inv-GNE to record#page4.tif source=P35574 Add inv-GNE to record#page5.tif source=P35574 Add inv-GNE to record#page6.tif source=P35574 Add inv-GNE to record#page7.tif source=P35574 Add inv-GNE to record#page8.tif source=P35574 Add inv-GNE to record#page9.tif source=P35574 Add inv-GNE to record#page10.tif source=P35574 Add inv-GNE to record#page11.tif source=P35574 Add inv-GNE to record#page12.tif source=P35574 Add inv-GNE to record#page13.tif source=P35574 Add inv-GNE to record#page14.tif source=P35574 Add inv-GNE to record#page15.tif	
RECEIPT INFORMATION EPAS ID: PAT6174713 Receipt Date: 06/26/2020	

CONFIRMATORY ASSIGNMENT

WHEREAS, Jessica Marie GRANDNER ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on Exhibit A (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

ASSIGNMENT I-A

Family No.: P35574
Genentech File Identifier: RHS Sulfones as Jak Inhibitors

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 11 June 2020, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Jessica Marie GRANDNER

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **US**



GENENTECH, INC.

Charles K. Sholtz
Associate General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35574-US	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	63/035381	5 June 2020

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P35574
Genentech File Identifier: RHS Sulfones as Jak Inhibitors

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P35574-US	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	63/035381	5 June 2020
P35574-US-1	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	16/902499	16 June 2020
P35574-WO-1	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	PCT/US2020/037853	16 June 2020
P35574-AR	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	P200101677	16 June 2020
P35574-GC	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	39922	16 June 2020
P35574-TW	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	109120272	16 June 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, **Daniel G. M. SHORE** ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, **GENENTECH, INC.**, a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the **INVENTION** and in and to the applications and patents to be obtained therefor, or, if **ASSIGNOR** has not assigned his or her interest in the **INVENTION** to **GENENTECH** pursuant to a prior agreement with **GENENTECH**, acquiring an interest in and to the **INVENTION**, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, **ASSIGNOR** confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), **ASSIGNOR** had assigned to **GENENTECH**, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


To the extent that **ASSIGNOR** has not already assigned all of his or her rights, title and interest in the **INVENTION** to **GENENTECH** via a prior agreement with **GENENTECH**, then for good and valuable consideration the receipt of which is hereby acknowledged, **ASSIGNOR** does hereby assign to **GENENTECH**, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The **ASSIGNOR** agrees and authorizes **GENENTECH**, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by **GENENTECH**, its successors, assigns and delegates in and to the **INVENTION** when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by **ASSIGNOR**. **ASSIGNOR** agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of **GENENTECH**, its successors, assigns or delegates, and shall be binding upon the **ASSIGNOR**, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 10 June 2020, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Daniel G. M. SHORE

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **CA**



GENENTECH, INC.

Charles K. Sholtz

Associate General Counsel

Genentech, Inc.

Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35574-US	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	63/035381	5 June 2020

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P35574
Genentech File Identifier: RHS Sulfones as Jak Inhibitors

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P35574-US	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	63/035381	5 June 2020
P35574-US-1	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	16/902499	16 June 2020
P35574-WO-1	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	PCT/US2020/037853	16 June 2020
P35574-AR	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	P200101677	16 June 2020
P35574-GC	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	39922	16 June 2020
P35574-TW	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	109120272	16 June 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, **Marian C. BRYAN** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, **GENENTECH, INC.**, a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the **INVENTION** and in and to the applications and patents to be obtained therefor, or, if **ASSIGNOR** has not assigned his or her interest in the **INVENTION** to **GENENTECH** pursuant to a prior agreement with **GENENTECH**, acquiring an interest in and to the **INVENTION**, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, **ASSIGNOR** confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), **ASSIGNOR** had assigned to **GENENTECH**, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


To the extent that **ASSIGNOR** has not already assigned all of his or her rights, title and interest in the **INVENTION** to **GENENTECH** via a prior agreement with **GENENTECH**, then for good and valuable consideration the receipt of which is hereby acknowledged, **ASSIGNOR** does hereby assign to **GENENTECH**, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The **ASSIGNOR** agrees and authorizes **GENENTECH**, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by **GENENTECH**, its successors, assigns and delegates in and to the **INVENTION** when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by **ASSIGNOR**. **ASSIGNOR** agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of **GENENTECH**, its successors, assigns or delegates, and shall be binding upon the **ASSIGNOR**, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 10 June 2020, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Marian C. BRYAN
Mailing address:
1 DNA Way
South San Francisco, CA 94080
Citizenship: **US**



GENENTECH, INC.
Charles K. Sholtz
Associate General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35574-US	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	63/035381	5 June 2020

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P35574-US	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	63/035381	5 June 2020
P35574-US-1	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	16/902499	16 June 2020
P35574-WO-1	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	PCT/US2020/037853	16 June 2020
P35574-AR	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	P200101677	16 June 2020
P35574-GC	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	39922	16 June 2020
P35574-TW	PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF	109120272	16 June 2020

